Lenacapavir (brand name Sunlenca) is a groundbreaking, FDA-approved, twice-yearly injectable medication used for both HIV prevention (PrEP) and...

Lenacapavir is an injectable treatment administered twice a year, making it a more convenient alternative to daily oral prevention drugs. The National...

Lenacapavir is an injectable treatment administered twice a year, making it a more convenient alternative to daily oral prevention drugs. The National...

Updated by Faith Barbara N Ruhinda at 1141 EAT on Thursday 26 February 2026 Uganda has taken delivery of its first consignment of Lenacapavir, a...

Updated by Faith Barbara N Ruhinda at 1141 EAT on Thursday 26 February 2026 Uganda has taken delivery of its first consignment of Lenacapavir, a...

A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two...

The federal government says consignments of Lenacapavir, a new drug for HIV prevention, are expected to arrive in Nigeria in March 2026. In a...

WEDNESDAY, March 11, 2026 -- The U.S. Food and Drug Administration has approved Sotyktu (deucravacitinib) for the treatment of adults with active...

WEDNESDAY, March 11, 2026 -- The U.S. Food and Drug Administration has approved Sotyktu (deucravacitinib) for the treatment of adults with active...

Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at Week 16 in the pivotal Phase 3...